	Application No.	Applicant(s)
	09/532,263	HILTON, DOUGLAS JAMES
Notice of Allowability	Examiner	Art Unit
·	Prema M. Mertz	1646
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this a or other appropriate communication GHTS. This application is subject	pplication. If not included on will be mailed in due course. THIS
1. This communication is responsive to the amendment filed 3	<u>3/25/2005</u> .	
2. The allowed claim(s) is/are 8-9, 11, renumbered 1-2, 3, res	pectively.	
3. \boxtimes The drawings filed on <u>22 March 2000</u> are accepted by the f	Examiner.	
 4. Acknowledgment is made of a claim for foreign priority una) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submit 	been received. been received in Application No. cuments have been received in this of this communication to file a repl ENT of this application. tted. Note the attached EXAMINE	s national stage application from the y complying with the requirements R'S AMENDMENT or NOTICE OF
INFORMAL PATENT APPLICATION (PTO-152) which give 6. CORRECTED DRAWINGS (as "replacement sheets") mus (a) including changes required by the Notice of Draftsperso 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date	t be submitted. on's Patent Drawing Review(PTC	D-948) attached
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the		
7. DEPOSIT OF and/or INFORMATION about the depose attached Examiner's comment regarding REQUIREMENT F	SIT OF BIOLOGICAL MATERIAL FOR THE DEPOSIT OF BIOLOGIC	must be submitted. Note the CAL MATERIAL.
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/06 Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview Summar Paper No./Mail Da 8), 7. ⊠ Examiner's Amend	ate
•		PREMA MERTZ PRIMARY EXAMINER

Page 2

Application/Control Number: 09/532,263

Art Unit: 1646

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 3/25/2005 has been entered.

- 2. Claims 1-7, 10, 12-34 have been canceled. Amended claim 8 (3/25/2005) and previously presented claims 9, 11 are pending.
- 3. Claims 8-9, 11 are allowable and have been renumbered 1-2, 3, respectively.
- 4. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Xiaochun Zhu on 5/2/2005.

5. The application has been amended as follows:

CLAIM 8 HAS BEEN AMENDED TO READ AS FOLLOWS:

Application/Control Number: 09/532,263 Page 3

Art Unit: 1646

Claim 8 (currently amended) An isolated nucleic acid molecule wherein the nucleic acid molecule encodes an α chain of human Interleukin (IL)-11 receptor wherein said IL-11 receptor comprises the amino acid sequence set forth in SEQ ID NO:5.

6. The following is an Examiner's Statement of Reasons for Allowance:

None of the prior art of record describe or suggest an isolated nucleic acid molecule wherein the nucleic acid molecule encodes an α chain of human Interleukin (IL)-11 receptor wherein said IL-11 receptor comprises the amino acid sequence set forth in SEQ ID NO:5

7. Any comments considered necessary by applicant must be submitted no later than the payment of the Issue Fee and, to avoid processing delays, should preferably **accompany** the Issue Fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7.00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (571) 272-0829.

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Prema Mertz Ph.D. Primary Examiner Art Unit 1646 Application/Control Number: 09/532,263

Art Unit: 1646

May 2, 2005

Page 4